Immunomodulatory effect of isoprinosine in chronic active B virus positive hepatitis: A comparative study with levamisole

A. Par, M. Paal, I. Hollos, P. Nemeth, J. Szekeres-Bartho, J. Sip os, E. Kerekes, T. Javor

Research output: Contribution to journalArticle

3 Citations (Scopus)


The host organism in hepatitis B virus (HBV)-related liver disease may need an immunostimulatory support for an appropriate immune response against the virus and for recovery. The effect of the potent immunomodulatory drug isoprinosine has been studied in comparison with levamisole. Nineteen patients with chronic active hepatitis B virus were assigned at random to receive either isoprinosine or levamisole. Nine patients were given isoprinosine at a daily dose of 3.0 g, while ten subjects wer given levamisole at a weekly dose of 300 mg. The treatment lasted for 1 month. Clinical signs, biochemical liver tests, immunoglobulins, auto-antibodies, lymphocyte subsets (T4 and T8 cell count), lymphoblastic transformation to phytohaemagglutinin, natural killer cells activity and HBV markers (HBsAg, HBeAg, anti-HBs, anti-HBe, anti-HBc) were determined before and after the treatment. T4 cell count and T4/T8 ratio increased only in the isoprinosine group and the lymphoproliferative response was also enhanced due to isoprinosine compared to levamisole. A slight elevation in serum HBsAg and anti-HBc levels was noted in some cases in parallel with an increase in total T cell count, T4/T8 ratio and lymphoproliferative response. It seems that isoprinosine is better than levamisole in restoring defective cellular immunity and may enhance the immune attack to HBV-infected liver cells. The immunomodulatory effects of isoprinosine can be of benefit in the treatment of chronic active HBV-positive hepatitis.

Original languageEnglish
Pages (from-to)43-50
Number of pages8
JournalInternational Journal of Immunotherapy
Issue number1
Publication statusPublished - Dec 1 1989


ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this